Developers brush off antitrust scrutiny and drug price curbs and succumb to the urge to merge.
Several big groups’ portfolios are ageing, and regulatory action risks blocking their renewal.
Asian developers dominate biopharma’s gout pipeline, with Selecta and Sobi’s SEL-212 standing out as a rare globally focused project.
Amgen might yet prevail in its attempt to buy Horizon, but the FTC shockwaves will still be felt.
The FTC moves to block Amgen’s Horizon takeout, broadening its remit to curb anticompetitive moves that inflate drug prices.
If forecasts prove accurate 2023 could be the biggest year for blockbuster launches for some time.
Forthcoming data will see the group take on Horizon, but subcutaneous projects could pose the real threat.